Oppenheimer Starts Sensei Biotherapeutics (SNSE) at Outperform, $36 PT

March 1, 2021 8:41 AM EST
Get Alerts SNSE Hot Sheet
Price: $14.13 -4.46%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 14 | New: 42
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Oppenheimer analyst Kevin DeGeeter initiates coverage on Sensei Biotherapeutics (NASDAQ: SNSE) with an Outperform rating and a price target of $36.00.

The analyst commented, "Initiating coverage of SNSE with Outperform rating and $36 price target based on 1) ImmunoPhage platform delivering hybrid off-the-shelf/personalized product profile to boost activity of PD-1 inhibitors; 2) low-cost modular production process allowing for fast turnaround time of four weeks and improved COGs versus first-generation personalized neoepitope products; and 3) expectation that SNS-301 in combination with PD-1 inhibitors will demonstrate differentiated PFS of 8-10 months in 1st-line head and neck squamous cell carcinoma (HNSCC). Furthermore, we view SNS-401 for MCC as an underappreciated asset and important POC for combination of off-theshelf and personalized ImmunoPhage. Our $36 PT is based primarily on SNS-301 generating 2029 revenues of $681.7M in 1st-line treatment and neoadjuvant HNSCC."

For an analyst ratings summary and ratings history on Sensei Biotherapeutics click here. For more ratings news on Sensei Biotherapeutics click here.

Shares of Sensei Biotherapeutics closed at $17.80 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

S3